ganoderma lucidum and endocrine

Introduction

Ganoderma lucidum, commonly known as Reishi or Lingzhi, is a medicinal mushroom traditionally used in East Asia for its health-promoting properties. Recent research has explored its potential effects on various health conditions, including its impact on endocrine-related functions and cancer therapies.

Key Insights

Cancer-Related Fatigue and Quality of Life:
- Spore powder of Ganoderma lucidum significantly improves physical well-being, reduces fatigue, and enhances the quality of life in breast cancer patients undergoing endocrine therapy.
Anti-Cancer Mechanisms:
- Ganoderma lucidum inhibits tumor growth and angiogenesis by down-regulating VEGF and TGF-beta1 secretion in prostate cancer cells.
- It suppresses the motility and invasion of breast and prostate cancer cells by inhibiting AP-1 and NF-kappaB signaling pathways.
- Ganoderma lucidum enhances the sensitivity of ovarian cancer cells to cisplatin and induces apoptosis through caspase 3 activation and p53 upregulation.
- Ganoderic acid T from Ganoderma lucidum induces apoptosis in lung cancer cells via mitochondrial dysfunction and p53 expression.
Immune System Modulation:
- Polysaccharides from Ganoderma lucidum activate and mature dendritic cells through NF-kappaB and p38 MAPK pathways, enhancing immune responses.
- Ganoderma lucidum stimulates NK cell cytotoxicity by increasing NKG2D/NCR activation and secretion of perforin and granulysin.
Endocrine-Related Effects:
- Ganoderma lucidum down-regulates estrogen receptor (ER) and NF-kappaB signaling, inhibiting the proliferation of both estrogen-dependent and independent breast cancer cells .
- Network pharmacology analysis identified key targets such as AR, ESR1, and PGR, suggesting that Ganoderma lucidum may regulate endocrine pathways in cancer treatment.

Conclusion

Ganoderma lucidum exhibits significant potential in improving cancer-related fatigue and quality of life in patients undergoing endocrine therapy. It also demonstrates robust anti-cancer properties by inhibiting tumor growth, angiogenesis, and cell motility, while enhancing the efficacy of conventional chemotherapy. Additionally, Ganoderma lucidum modulates immune responses and affects endocrine-related pathways, making it a promising candidate for integrative cancer therapies.

Ganoderma lucidum and endocrine

Summary

Introduction

Key Insights

Conclusion

Sources and full results

Spore Powder of Ganoderma lucidum Improves Cancer-Related Fatigue in Breast Cancer Patients Undergoing Endocrine Therapy: A Pilot Clinical Trial

Spore powder of Ganoderma lucidum may improve cancer-related fatigue and quality of life in breast cancer patients undergoing endocrine therapy without significant adverse effects.

Network pharmacology analysis of the anti-cancer pharmacological mechanisms of Ganoderma lucidum extract with experimental support using Hepa1-6-bearing C57 BL/6 mice.

Ganoderma lucidum extract effectively inhibits tumor growth in Hepa1-6-bearing C57 BL/6 mice, with potential mechanisms involving up-regulation of PGR and ESR1 and down-regulation of NR3C2 and AR.

Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells.

Ganoderma lucidum inhibits prostate cancer-dependent angiogenesis by modulating MAPK and Akt signaling, potentially offering potential therapeutic use for prostate cancer treatment.

Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells.

Ganoderma lucidum spores and fruiting body inhibit highly invasive breast and prostate cancer cell motility through a common mechanism, suggesting potential therapeutic use for cancer treatment.

Polysaccharide purified from Ganoderma lucidum induced activation and maturation of human monocyte‐derived dendritic cells by the NF‐κB and p38 mitogen‐activated protein kinase pathways

PS-G from Ganoderma lucidum effectively promotes activation and maturation of immature dendritic cells, suggesting potential in regulating immune responses.

Ganoderma lucidum exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin.

Ganoderma lucidum has multiple anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin, potentially offering a promising treatment option for ovarian cancer.

Functions of the nicotinamide adenine dinucleotide phosphate oxidase family in Ganoderma lucidum: an essential role in ganoderic acid biosynthesis regulation, hyphal branching, fruiting body development, and oxidative-stress resistance.

NoxA and NoxB in Ganoderma lucidum play central roles in hyphal branching, fruiting body development, reactive oxygen species generation, and ganoderic acid biosynthesis regulation, suggesting a conserved signal-crosstalk mechanism in plants, animals, and fungi.

Ganoderma lucidum inhibits proliferation of human breast cancer cells by down-regulation of estrogen receptor and NF-kappaB signaling.

Ganoderma lucidum inhibits human breast cancer cell proliferation by modulating estrogen receptor and NF-kappaB signaling, making it a potential herb for chemoprevention and chemotherapy.

Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells.

Ganoderic acid T (GA-T) from Ganoderma lucidum mycelia induces apoptosis in metastatic lung cancer cells through mitochondrial dysfunction and p53 expression, making it a potential useful chemotherapeutic agent.

Ganoderma lucidum stimulates NK cell cytotoxicity by inducing NKG2D/NCR activation and secretion of perforin and granulysin

Ganoderma lucidum stimulates NK cell cytotoxicity against various cancer cells by activating NKG2D/NCR receptors and MAPK signaling pathways, leading to the secretion of perforin and granulysin.

Try another search